References
1.Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579: 265-269.
2.A.A. Elfiky, S.M. Mahdy, W.M. Elshemey. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses, J. Med. Virol. 89 (2017) 1040–1047
3. Furuta, , Komeno, T., Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B. 2017; 93: 449-463
4.Warren, T.K., Jordan R, Lo K M, Ray A S ,Mackman RL, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys. Nature 2016; 531: 381-385
5. Beigel JH, Tomashek KM, Dodd LE, Mehta AK,. Zingman BS et al. Remdesivir for the treatment of Covid-19 — Preliminary Report. DOI: 10.1056/NEJMoa2007764
6.Rodríguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013; 11:1269–1279
7.Mariño Z, van Bömmel F, Forns X, et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 2014;63:207–215
9.Elfiky AA. Anti-HCV, nucleotide inhibitors, re-purposing against COVID-19. Life Sci 2020; 248:117477
10. Chien M, Anderson TK, Jockusch S, et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.18.997585
11.Ju, J., Li X, Kumar, S., Li, X., Jockusch, S. Chein M et al. Nucleotide analogues as inhibitors of viral polymerases. bioRXiv . 2020doi: https://doi.org/10.1101/2020.03.12.989186